<DOC>
	<DOCNO>NCT00724334</DOCNO>
	<brief_summary>The purpose study evaluate long-term effect orally administer SAR302503 ( TG101348 ) patient myelofibrosis complete MF-TG101348-001 study .</brief_summary>
	<brief_title>A Long-Term Study Effects Orally Administered SAR302503 Patients With Myelofibrosis</brief_title>
	<detailed_description>SAR302503 ( TG101348 ) potent small molecule inhibitor Janus kinase 2 ( JAK2 ) . This extension study first-in-man , dose escalation study ( MF-TG101348-001 ) . The safety , tolerability clinical activity SAR302503 ( TG101348 ) subject myelofibrosis evaluate .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Completion MFTG101348001 study Diagnosis myelofibrosis At least 18 year age Any acute chronic medical abnormality may increase risk associate study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>myelofibrosis</keyword>
</DOC>